Karyopherin a2 (KPNA2) is involved in carcinogenesis through translocation of cancer associated cargo proteins. The present study provides first data about KPNA2 in renal-cell carcinoma (RCC) in a cohort of 240 primary RCC tissues. KPNA2 expression on the protein and transcript level is an adverse factor in RCC and is correlated with higher tumor stage as well as higher tumor grade.
Introduction
Karyopherin a2 (KPNA2) is 1 of 7 members of the karyopherin a family and plays an important role in the nucleocytoplasmic transport system. KPNA2 forms heterodimers with karyopherin b1 (KPNB1). In this transport complex, KPNA2 recognizes cargo proteins through their nuclear localization signal and acts as an adapter. Cargo proteins are bound and translocated through nuclear pores. [1] [2] [3] [4] [5] [6] [7] KPNA2 seems to be involved in carcinogenesis through translocation of cancer-associated nuclear cargo proteins such as NBN, E2F1, OCT4, NFKB1, Myc, p53, FGF2, LEF-1, CHK2, BRCA1, S100A2, S100A6, RECQL, RAC1, and p65. [8] [9] [10] Overexpression of KPNA2 in cells promotes proliferation, cell growth, migration, invasion, and tumor formation. By contrast, KPNA2 silencing leads to suppression of proliferation, migration, invasion, and tumor formation. [11] [12] [13] [14] [15] [16] [17] [18] Increased apoptosis has also been described as a result of KPNA2 silencing. 13, 18 Meanwhile, numerous studies have shown an 1 association between KPNA2 expression and reduced overall survival in various solid tumors. 12, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] In addition, elevated serum levels of KPNA2 are reported for epithelial ovarian cancer, nonesmall-cell lung cancer, and esophageal squamous-cell carcinoma. 14, 24, 31 In earlier studies we demonstrated an adverse prognostic value of KPNA2 in prostate and breast cancer. 16, 25, 26 So far, the prognostic significance of KPNA2 in renal-cell carcinoma (RCC) is still unknown. We here present the first data about KPNA2 expression in RCC in a well-defined cohort of 240 primary RCC tumor samples.
Patients and Methods

Patient Population and Tumor Specimens
This study includes tissue samples of 240 patients with primary RCC who underwent surgery at the Department of Urology, Charité-Universitätsmedizin Berlin, between 1993 and 2004. The cohort consisted of 80 female (33.33%) and 160 male (66.67%) patients. The median age at the time of surgery was 61 years (range, 30-86 years). Clinical follow-up data were available for 235 patients of our cohort (97.92%). Median follow-up time of all cases was 134 months (range, 1-258 months). The cohort included clear-cell RCC (ccRCC; n ¼ 217, 
Tissue Microarray Construction
Tissue microarray construction was performed as previously described. 32 Each tumor was represented by 2 tissue cores. 
Evaluation of Immunoreactivity
KPNA2 protein expression was quantified by using the semiquantitative image analysis software Tissue Studio 2.1 (Definiens, Munich, Germany) as previously described. 33 Slides were digitalized with a Zeiss Mirax scanner (Carl Zeiss, Jena, Germany). After manually marking the tumor cells on tissue microarray slides to avoid mixing them up with nontumor cells, the program was run to quantify immunopositive and immunonegative tumor cell nuclei within the region of interest. The result was controlled with a screenshot, which showed a color-coded classification in immunopositive and immunonegative tumor cell nuclei. The positive index was derived from these data as the quotient of immunopositive and all tumor nuclei regardless of immunoreactivity. Tissue microarray cores were analyzed individually and an average score calculated.
Analysis of The Cancer Genome Atlas Data
Normalized messenger RNA (mRNA) expression data and clinical database were extracted for a well-described The Cancer Genome Atlas (TCGA) ccRCC cohort (data version 28.01.2016, number of patients ¼ 533) and a proper characterized pRCC cohort (data version 31.05.2016, number of patients ¼ 291). Among available ccRCC patients, 481 patients had follow-up information with overall survival as end point (number of events [death] at the end of follow-up ¼ 157). The pRCC cohort provided follow-up information with overall survival as the end point (number of events [death] at the end of the follow-up ¼ 42) for 290 patients. For KPNA2 mRNA expression, best cutoff selection was performed using the survMisc package (principle: consecutive evaluation of all available cutoffs using univariate Cox analysis).
Statistical Analysis
Statistical analysis was performed by SPSS 25 software for Windows (IBM, Armonk, NY) and R 3.4.4 (R Foundation for Statistical Computing, Vienna, Austria; http://www.r-project.org/). KPNA2 expression was correlated with clinicopathologic data available (tumor stage, nodal status, distant metastasis, ISUP grade, resection status, and sex) by Pearson correlation analysis. Survival time was estimated by Kaplan-Meier analyses and compared among patient subsets by log-rank tests. KPNA2 expression was also examined within univariate and multivariate Cox proportional hazards regression models. All statistical tests were 2 sided. P < .05 was considered statistically significant. 300  288  276  264  252  240  228  216  204  192  180  168  156  144  132  120  108  96  84  72  60  48  36 
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Results
KPNA2 Protein Expression in RCC and Tubular Epithelium
KPNA2 expression was almost exclusively restricted to nuclei of the cells. Only a few cases showed weak cytoplasmic staining. KPNA2 staining ranged from 0 to 79.50% of all tumor cells (median 0.25%, average 2.00%). Normal tubular epithelium frequently showed expression of KPNA2. The distribution ranged from 0 to 100% of all tubular cells (median 0.35%, average 1.29%). We did not observe significant differences in the protein expression in proximal and distal tubuli epithelium. The protein expression was classified into 2 groups as high and low/negative. High was defined as protein expression above the 80th percentile in normal tubular epithelium (1% positive cell nuclei); low/negative was determined as protein expression under the 80th percentile or no protein expression in normal tubular epithelium (<1% positive cell nuclei or no expression). High protein expression of KPNA2 was observed in 46 samples (19.17%) and in 163 (67.92%) of the analyzed tumor specimens that had low staining intensities. No immunoreactivity was observed in 31 tumor samples (12.92%) (Figure 1 ).
KPNA2 Protein Expression and Clinicopathologic Parameters
By Pearson correlation analysis, we found a correlation of higher KPNA2 expression with higher tumor grade (P ¼ .007) and higher tumor stage (P ¼ .031) in ccRCC. There was no correlation between KPNA2 expression with lymph node involvement, resection status, or gender (Table 1) . We observed no correlation between KPNA2 protein expression and the aforementioned clinicopathologic parameters in pRCC (data not shown). Interestingly, type 2 histomorphology of pRCC was correlated with higher KPNA2 expression (P ¼ .019)
KPNA2 Protein Expression and Survival Analyses
An inverse association between overall survival and KPNA2 expression in ccRCC was identified by Kaplan-Meier analysis. High KPNA2 expression was significantly associated with an adverse prognosis (log-rank test, P ¼ .011) (Figure 2 Table 2 ). In pRCC, no association between overall survival and KPNA2 protein expression was observed (data not shown).
Analysis of TCGA Cohort
We observed a significant difference in the expression of KPNA2 mRNA between normal renal tissue and ccRCC tissue samples (P ¼ .001). The mean expression of KPNA2 mRNA in ccRCC was 780.7 (range, 204.0-6214.9) and 657.6 in normal renal parenchyma (range, 358.2-1641.1). By Pearson correlation analysis, we detected a strong correlation of higher KPNA2 expression with higher tumor grade (P < .001), tumor stage (P < .001), and distant metastasis (P < .001). Kaplan-Meier analysis demonstrated a significantly shorter overall survival for the patients whose tumor showed high KPNA2 mRNA expression (P < .001) (Supplemental Figure 1 in the online  version) . The cutoff value of 792.8 that we used was derived by Cox modelebased selection and divided the cohort into 2 subgroups with low and high KPNA2 mRNA expression. Univariate Cox regression analysis for the selected cutoff value showed a HR of 2.31 (95% CI, Univariate Cox regression survival analysis revealed that tumor stage, pT (P < .001), nodal status, pN (P ¼ .001), residual tumor, R (P < .001), ISUP grade, G (P < .001), and KPNA2 protein expression (P ¼ .018) are associated with overall survival. Multivariate Cox regression analysis confirmed tumor stage pT (P ¼ .001), residual tumor R (P ¼ .001), and ISUP grade G (P ¼ .004) to be independent prognostic factors in ccRCC. P values <.05 were considered statistically significant.
Abbreviations: ccRCC ¼ clear-cell renal-cell carcinoma; CI ¼ confidence interval; HR ¼ hazard ratio; ISUP ¼ International Society of Urologic Pathology; KPNA2 ¼ karyopherin a2.
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1.69-3.16) with P < .001. At the transcript level, the prognostic value of KPNA2 expression was retained in multivariate Cox regression models with inclusion of tumor stage, nodal status, and tumor grade (P ¼ .035, HR ¼ 1.45; 95% CI, 1.03-2.05).
We conducted the same analysis for the pRCC TCGA cohort. KPNA2 mRNA was significantly (P < .001) more highly expressed in pRCC than in normal renal tissue samples. The mean expression of KPNA2 mRNA in pRCC was 782.6 (range, 154.4-3916.9) was and 576.7 (range, 378.9-911.0) in normal renal parenchyma. Higher tumor stage (P < .001), distant metastasis (P < .001), and type 2 histomorphology (P ¼ .015) were correlated with higher KPNA2 mRNA expression. By Kaplan-Meier analysis, we detected an inverse correlation between high KPNA2 mRNA expression and overall survival (P < .001) (Supplemental Figure 2 in the online version) . This result was confirmed by univariate Cox regression analysis (P < .001; HR ¼ 9.7; 95% CI, 5.1-18.4). In a multivariate Cox proportional hazards model, high expression of KPNA2 prevailed as a prognostic factor of patient outcome in pRCC when verified together with recognized prognostic factors like tumor stage, nodal status, and histomorphologic subtype (P ¼ .004; HR ¼ 6.2; 95% CI, 2.3-16.9).
Discussion
To our knowledge, the present study is the first to describe KPNA2 expression in RCC. KPNA2 is involved in the exchange of molecules between the nucleus and cytoplasm as a carrier protein. [1] [2] [3] [4] [5] [6] [7] The nucleocytoplasmic transport system plays an important role in carcinogenesis by promoting the transport of cancer-associated proteins like NBN, E2F1, OCT4, NFKB1, Myc, p53, FGF2, LEF-1, CHK2, BRCA1, S100A2, S100A6, RECQL, RAC1, and p65. [8] [9] [10] In this way KPNA2 is indirectly involved in several biological processes like proliferation, cell growth, migration, invasion, and tumor formation.
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The findings of this study are in line with recently reported studies showing that a subgroup of tumors with increased KPNA2 expression is correlated with poor prognosis in numerous solid malignancies. 12, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Similarly, Kaplan-Meier survival analysis demonstrated that high KPNA2 protein expression is associated with adverse prognosis in ccRCC. But KPNA2 protein expression seems to be less important compared to well-established prognostic factors like tumor stage, lymph node metastasis, ISUP grade, and resection status. In addition, we found a positive correlation between KPNA2 protein expression and advanced tumor stage and higher ISUP grade, indicating that KPNA2 might be important in the progression of ccRCC. Analysis of TCGA data confirmed the immunohistochemical findings, also showing an association between high KPNA expression on mRNA level and shorter overall survival in Kaplan-Meier analysis as well as univariate Cox regression model. Furthermore, KPNA2 mRNA expression is an independent prognostic factor in multivariate Cox regression models when tested together with tumor stage, nodal status, and tumor grade. In addition, KPNA2 mRNA expression was also correlated with lymph node involvement and distant metastasis. Unfortunately, we could not confirm the impact of KPNA2 expression on the process of distant metastasis at the protein level because of missing information about distant metastasis. Despite these differences in the results of mRNA and protein levels, the findings of the present study point in the same direction, demonstrating that high KPNA2 expression is an adverse factor in ccRCC. We did not discover an association between KPNA2 protein expression and overall survival or of clinicopathologic parameters in pRCC. In contrast, at the transcript level, high KPNA2 expression was correlated with higher tumor stage, positive nodal status, and distant metastasis. In addition, high KPNA2 mRNA expression was identified as an independent prognostic factor in pRCC. It is important to mention that because of the low number of pRCCs (n ¼ 23) in our cohort, the findings of the present study do not allow a comprehensive conclusion at the protein level. It might be a task of future studies to examine the impact of KPNA2 protein expression in a larger cohort of this subtype. It is worth mentioning that there is no broadly accepted score for measuring KPNA2 protein expression in formalinfixed, paraffin-embedded specimens. Previous studies to date have used different scoring systems and cutoff values in different tumor entities. The selected cutoff value of 1% positive cell nuclei represents the 80th percentile in corresponding benign tubular epithelium. This value provided the best prediction of patient prognosis in ccRCC. Because of the delicate differences in KPNA protein expression in RCC, we decided to quantify the protein expression by using semiquantitative image analysis software. The resulting reduction of the intra-and interobserver variability ensured the crystallization of small differences in KPNA2 protein expression among the tumors. 33 
Conclusion
KPNA2 expression is elevated in a subset of ccRCC and pRCC, and represents a novel prognostic factor in these subtypes of RCC. In consideration of the fact that high expression of known cargo proteins of KPNA2 like p53 and FGF2 are important in the pathogenesis of ccRCC, [34] [35] [36] [37] the investigation of the nucleocytoplasmic transport through KPNA2 in ccRCC is an important task for future studies in order to better understand the link between elevated KPNA2 expression and altered biological processes like proliferation, cell growth, migration, invasion, and tumor formation in RCC. Further functional studies are clearly warranted. In addition, examination of other mnembers of karyopherin a family could elucidate the role of the nucleocytoplasmic transport system in the pathogenesis of RCC.
Clinical Practice Points
KPNA2 expression is an adverse prognostic factor in RCC. Higher tumor stage and higher tumor grade are correlated with high KPNA2 expression. KPNA2 expression could be used to stratify risk groups within RCC.
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